Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
Troya J, Montejano R, Ryan P, Gómez C, Matarranz M, Cabello A, Vera F, Sepúlveda MA, Santos I, Samperiz G, Bachiller P, Boix V, Barrufet P, Cervero M, Sanz J, Solís J, Yllescas M, Valencia E; GESIDA-8715 Study Group. Troya J, et al. Among authors: matarranz m. PLoS One. 2018 Jun 14;13(6):e0198768. doi: 10.1371/journal.pone.0198768. eCollection 2018. PLoS One. 2018. PMID: 29902204 Free PMC article.
Oral bulky lesions related to advanced HIV infection.
Troya J, Matarranz M. Troya J, et al. Among authors: matarranz m. Postgrad Med J. 2020 Feb;96(1132):114. doi: 10.1136/postgradmedj-2019-137093. Epub 2019 Sep 26. Postgrad Med J. 2020. PMID: 31558685 No abstract available.
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Fanciulli C, et al. HIV Med. 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. Epub 2022 Jan 17. HIV Med. 2022. PMID: 35037379 Free PMC article.
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, De La Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, De Miguel M, Jarrín I, González-García J; GeSIDA 8514 Study Group. Pérez-Latorre L, et al. Euro Surveill. 2021 Jun;26(25):2000236. doi: 10.2807/1560-7917.ES.2021.26.25.2000236. Euro Surveill. 2021. PMID: 34169818 Free PMC article.
Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients.
Valle-Millares D, Brochado-Kith Ó, Martín-Carbonero L, Domínguez-Domínguez L, Ryan P, De Los Santos I, De la Fuente S, Castro JM, Lagarde M, Cuevas G, Mayoral-Muñoz M, Matarranz M, Díez V, Gómez-Sanz A, Martínez-Román P, Crespo-Bermejo C, Palladino C, Muñoz-Muñoz M, Jiménez-Sousa MA, Resino S, Briz V, Fernández-Rodríguez A, On Behalf Of Multidisciplinary Group Of Viral Coinfection Hiv/Hepatitis Covihep. Valle-Millares D, et al. Among authors: matarranz m. Biomedicines. 2021 Nov 5;9(11):1627. doi: 10.3390/biomedicines9111627. Biomedicines. 2021. PMID: 34829855 Free PMC article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
52 results